Underwriters are also getting better at detecting GLP-1 use through: Prescription databases Medical records requests Follow-up health questionnaires What This Means for Your Clients If currently on GLP-1 medications: Expect questions about medication use and duration Be prepared for potentially higher rates despite current health improvements Consider timing of application if they've been stable on medication for an extended period If recently stopped GLP-1 medications: Underwriters may view recent discontinuation as a risk factor Weight regain could further complicate the application process Medical follow-up showing sustained health improvements may help If planning to start GLP-1 medications: Understand that future applications may be affected by medication use Industry Trends to Watch Some forward-thinking insurance companies are exploring partnerships with GLP-1 providers to improve medication adherence
But my stomach hurt for a bit and then subsided
People with diabetes, particularly severe diabetes, tend to lose less weight with GLP-1s than people without diabetes, so microdosing is less likely to be as effective, though their dose should only be increased as they tolerate it. George said that in her professional opinion, microdosing is a potential option for patients with smaller amounts of weight to lose or as a bridge to start, or wean off, regular GLP-1 medications
Also consider: How quickly is the weight changing
These medications, such as Ozempic and Wegovy, have revolutionized the treatment landscape for obesity and type 2 diabetes, yet the journey can be rocky due to these side effects
Here's what each one looks like and when to use it